If the vaccine called ChAd3-EBO-Z is ultimately found to be safe and effective, it could offer crucial protection for contacts (family members, neighbours, etc) of patients with confirmed Ebola disease in future epidemics, thereby helping to interrupt transmission.
The study, carried out in Mali, West Africa and Baltimore in US, included the first testing of this vaccine in adult health care workers and other at-risk persons in Africa. It identified the dose to be used in subsequent clinical trials and for large-scale manufacture of the vaccine.     

"This is a crucial step on the road to using this vaccine in humans," said Dr Myron M Levine from UM SOM. "This gives us essential information that the vaccine is not only well-tolerated but the high dose stimulates strong immune responses in adults in West Africa, the global region
where the Ebola outbreak was rampant last year," said Levine.
The vaccine consists of an adenovirus (cold virus) that has been modified so that, in humans, it does not cause illness and cannot multiply. It does not contain the entire virus, but a single Ebolaprotein. Immune responses directed against this attachment protein have been shown to be highly protective in animal studies.
The study was published in the journal Lancet Infectious Disease.



Latest News from Lifestyle News Desk